Quantcast

Cold-EEZE(R) Lozenges not Affected by FDA Advisory for Zicam(R) Intra-Nasal Products

June 16, 2009

DOYLESTOWN, Pa., June 16 /PRNewswire-FirstCall/ — The U.S. Food and Drug Administration (FDA) today advised consumers to stop using three intra-nasal products (gels and swabs) marketed over-the-counter as cold remedies under the Zicam(R) brand because the use of these intra-nasal products are associated with the loss of sense of smell (a condition called anosmia).

While these products are manufactured with a zinc ingredient, The Quigley Corporation (Nasdaq: QGLY), www.quigleyco.com, maker of the popular line of Cold-EEZE(R) zinc gluconate lozenges, assures consumers that their oral zinc lozenge products are not involved in this new FDA advisory, and that the Cold-EEZE(R) brand continues to be supported as safe and effective in clinical research. Only intra-nasal products have shown any association with anosmia.

“The introduction of zinc ions orally has not been connected with the loss of smell,” says Darrell T. Hulisz, R.Ph., PharmD, clinical pharmacist/researcher and associate clinical professor at Ohio Northern University College of Pharmacy. “The safe and efficacious use of oral zinc gluconate lozenges is well established.”

“The FDA has made a determination that the Zicam intra-nasal products have a growing body of evidence suggesting that they may pose a safety risk to consumers who use them,” says Albert Piechotta, executive director of communications at The Quigley Corporation. “Cold-EEZE zinc lozenges have been shown to safely reduce the duration and severity of cold symptoms by nearly half in two clinical studies and have no history of causing adverse events related to anosmia in clinical studies or safety studies.”

Since their introduction 14 years ago, Cold-EEZE lozenges have had an outstanding record of safety. Customers can be assured that Cold-EEZE lozenges will continue to be available and is not affected by the FDA’s decision to request Zicam remove its nasal products from store shelves.”

For more information about Cold-EEZE(R), visit www.coldfight360.com.

About The Quigley Corporation

The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, gums and sugar free tablets clinically proven to cut the common cold nearly in half. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has several wholly owned subsidiaries; Quigley Manufacturing Inc. consists of two FDA approved facilities to manufacture COLD- EEZE(R) lozenges as well as fulfill other contract manufacturing opportunities. Quigley Pharma Inc. (http://www.QuigleyPharma.com) conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived potential prescription drugs.

Forward-Looking Statements

Certain statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company’s actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.

    Media Contact:
    Alyson O'Mahoney
    Robin Leedy & Associates
    (914) 241-0086, ext. 13
    or
    Albert Piechotta, Executive Director of Communications
    The Quigley Corporation
    (215) 345-0919, ext. 122

    Investor Relations Contact:
    Carl Hymans
    G.S. Schwartz & Co.
    212-725-4500-ext 304
    carlh@schwartz.com

SOURCE Quigley Corporation


Source: newswire



comments powered by Disqus